rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INMB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceINMBNCNA
      INmune Bio, Inc. Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceINMB
      INmune Bio Inc (INMB) Q3 2026 Earnings Call Highlights: UK Approval Path for Ebstracell Narrows ...
      Nov 6Yahoo FinanceINMB
      INmune Bio Q3 2026 Earnings Call Transcript
      Nov 5BenzingaINMB
      INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
      Nov 5Yahoo FinanceINMB
      MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
      Nov 5Yahoo FinanceINMB
      INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
      Oct 29Yahoo FinanceINMB
      Exclusive BAC Article: INmune Bio; Full MAA Submission Ebstrocel RDEB Feb 2027, U.S BLA Submission Same Program Q2 2027, XPro Phase 2b/3 Protocol Study Package Submission AD Q4 2026, And Catalysts (NASDAQ:INMB)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be INmune Bio Inc. (INMB).

      Oct 28Seeking AlphaINMB
      INmune Bio announces $4.5M registered direct offering
      Oct 28Investing.comINMB
      INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
      Oct 28Yahoo FinanceINMB
      INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB)
      Oct 23Seeking AlphaINMBKRYS
      INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

      Detailed price information for Inmune Bio Inc (INMB-Q) from The Globe and Mail including charting and trades.

      Oct 22The Globe and MailINMB
      Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel
      Oct 21Yahoo FinanceINMB
      INmune Bio submits pre-approval package to UK regulator for RDEB
      Oct 21Investing.comINMB
      INmune Bio partners with Uniphar for Ebstrocel distribution
      Oct 21Investing.comINMB
      INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
      Oct 21Yahoo FinanceINMB
      INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
      Oct 21Yahoo FinanceINMB
      Can Quantum Computing (QUBT) Be A Bargain As Its INmune Bio Deal Opens Biopharma?
      Oct 16Yahoo FinanceINMBQUBT
      Quantum Technology Meets Biotechnology: INmune Bio and Quantum Computing Inc. Team Up to Accelerate Drug Discovery
      Oct 15TheStreetINMBQUBT
      QCi and INmune Bio partner to study XPro in Alzheimer’s

      Both companies will analyse clinical and biomedical datasets to identify conditions that share the biological mechanisms targeted by XPro.

      Oct 15Yahoo FinanceINMB
      INmune Bio partners with Quantum Computing for drug research
      Oct 14Investing.comINMB
      INmune Bio, Quantum Computing Team Up to Identify New Uses for Alzheimer's Drug
      Oct 14Yahoo FinanceINMB
      INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzhei
      Oct 14BenzingaINMBQUBT
      Full Transcript: INmune Bio Q2 2026 Earnings Call - INmune Bio (NASDAQ:INMB)

      INmune Bio (NASDAQ:INMB) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

      Oct 12BenzingaINMB
      INmune Bio to Attend the 2026 Maxim Growth Summit

      BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. INmune Bio

      Oct 6Yahoo FinanceINMB
      INmune Bio at H.C. Wainwright conference: rdeB drug nears filings
      Sep 14Investing.comINMB
      INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
      Sep 14Yahoo FinanceINMB
      INmune Bio to Present at the H.C. Wainwright Global Investment Conference

      The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced their attendance at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 at the Lotte New York Palace Hotel in New York City. David Moss, Founder and Chief Executive Officer, will be ho

      Sep 9Yahoo FinanceINMB
      INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB)

      INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.

      Aug 28Seeking AlphaINMB
      INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

      Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity BOCA RATON, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it h

      Aug 26Yahoo FinanceINMB
      INmune Bio submits EU regulatory filings for Ebstrocel in RDEB
      Aug 26Investing.comINMB

      This is the newest page. Registered accounts read further back.